Cello Health PLC Total Voting Rights (0551Y)

TIDMCLL

RNS Number : 0551Y

Cello Health PLC

16 August 2018

16 August 2018

Cello Health plc

Total Voting Rights

In conformity with the FCA's Disclosure Guidance and Transparency Rules, Cello Health plc ("Cello" or the "Company") confirms the following:

As at 16 August 2018, Cello's issued share capital consists of 105,164,241 ordinary shares of 10 pence each ("Ordinary Shares"). The Company holds 453,000 Ordinary Shares in treasury. The total number of current voting rights in the Company is therefore 104,711,241 Ordinary Shares.

The above figure (104,711,241 Ordinary Shares) may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

 
                                      020 7812 
 Cello Health plc                      8460 
 Mark Scott, Chief Executive 
 Mark Bentley, Finance Director 
 
                                      0207 397 
 Cenkos Securities (Nomad)             8900 
 Mark Connelly / Harry Hargreaves 
                                      0207 466 
 Buchanan Communications               5000 
 Mark Court 
  Jamie Hooper 
  Sophie Wills 
 

About Cello Health plc

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

TVRLQLFFVVFXBBL

(END) Dow Jones Newswires

August 16, 2018 09:00 ET (13:00 GMT)